Fig. 4: CNS outcomes. | Nature Communications

Fig. 4: CNS outcomes.

From: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial

Fig. 4

CNS activity of the alectinib plus bevacizumab combination in ALK-rearranged NSCLC. A Cumulative incidence of brain metastasis in patients without brain lesions at diagnosis; B Intracranial progression-free survival in the intended-to-treat population. C Swimmer plot of the course of the patients with baseline BM (n = 7), showing duration of response (DOR), time on the experimental therapy, time without bevacizumab, CNS progression, deaths, adverse events, and ongoing treatment according EML4-ALK variant type. D Best percentage of tumor shrinkage in the CNS.

Back to article page